Search Type: drug or dietary supplement name
Search Term: itraconazole (ONMEL, SPORANOX, TOLSURA)

Drug Profiles | Worst Pills, Best Pills Newsletter Articles | Additional Information from Public Citizen | Health Letter Articles

Drug and Dietary Supplement Profiles

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include drug profiles where your selected drug is a secondary subject of discussion

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion
  • FDA Warning: Commonly Used Diarrhea Drug Can Cause Life-Threatening Heart Problems [hide all summaries]
    (May 2017)
    Find out which commonly used prescription and over-the-counter diarrhea medications can cause dangerous abnormal heart rhythms and cardiac arrest if taken at higher-than-recommended doses.
  • FDA Restricts, EMA Moves to Ban Ketoconazole Tablets [hide all summaries]
    (January 2014)
    A dangerous and easily substituted antifungal drug presents yet another example of Europeans being more protected from dangerous medicines by their regulatory authorities than Americans.
  • Watch out for Interactions Between Drugs for Erectile Dysfunction and Other Medications [hide all summaries]
    (January 2009)
    The article lists 56 drugs that can interact with the three drugs for erectile dysfunction (ED): sildenafil (VIAGRA), tadalafil (CIALIS) and vardenafil (LEVITRA). Eight of the drugs are either nitrates such as nitroglycerin or a certain group of high blood pressure drugs.In combination with ED drugs, these drugs can cause a dangerous fall in blood pressure that could lead to a heart attack or stroke. Thirty-two other drugs can inhibit the enzyme that helps the body to eliminate the ED drugs, resulting in abnormally high blood levels of the drugs and a potentially harmful "overdose" even though you are actually taking the recommended amount. The other 16 drugs speed up the metabolism of the ED drugs, thereby lowering the blood levels and reducing the effectiveness of the ED drugs.
  • Calcium Channel Blocker Drug Interactions [hide all summaries]
    (May 2008)
    This article lists more than 60 prescription drugs that can interact with calcium channel blocking drugs such as amlodipine (NORVASC),diltiazem (CARDIZEM, DILACOR XR TIAZAC)or nifedipine (PROCARDIA)to either cause toxicity or to lessen the effectiveness of the calcium channel blocking drugs. Included in the lists are a number of drugs that we list in Worst Pills, Best Pills as DO NOT USE or LIMITED USE drugs. The article also explains the different kinds of toxicity that can ensue from these interactions.
  • SSRIs Can Have Dangerous Interactions With Other Drugs [hide all summaries]
    (January 2008)
    More than 70 million prescriptions a year are filled for these popular antidepressants, including Prozac, Paxil, Zoloft, Luvox, Celexa and Lexapro. This article gives details about more than 60 other widely prescribed prescription drugs that can have harmful interactions if used with these antidepressants. The two different kinds of interactions are also discussed.
  • Using Oral Terbinafine (LAMISIL) for Fungal Infections Poses Risks to Your Health [hide all summaries]
    (January 2007)
    Serious health complications involving toxicity to the bone marrow have been reported in association with the drug terbinafine (LAMISIL), according to the August 2006 edition of the Australian Adverse Drug Reactions Bulletin. This is in addition to the hundreds of cases of liver toxicity that were the cause of our listing this drug as Do Not Use.
  • Extensive New Warnings for the Potent Pain Drug Fentanyl Transdermal System (DURAGESIC) [hide all summaries]
    (October 2005)
    As the black box warning suggests, fentanyl skin patches should not be used in the following situations:in patients who have not previously been prescribed opioid painkillers, in the management of acute pain or in patients who require opioid pain killers only for a short period of time.
  • The Widely Used Antibiotic Erythromycin And Fatal Heart Rhythm Disturbances [hide all summaries]
    (November 2004)
    You should not take erythromycin in combination with one of the interacting drugs listed in this article. If you are, you should contact your physician immediately. As mentioned above, erythromycin is an important antibiotic when used appropriately. Therefore, we do not recommend against its use when it is not used with one of these interacting drugs.
  • DO NOT USE UNTIL 2011 Eplerenone (INSPRA) For High Blood Pressure [hide all summaries]
    (December 2003)
    This statement appears in the professional product labeling, or package insert, for eplerenone: “The principal risk of INSPRA is hyperkalemia. Hyperkalemia can cause serious, sometimes fatal, arrhythmias (heart rhythm disturbances).”

Additional Information from Public Citizen

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion
  • Statement at FDA Hearing on Risk Management of Prescription Drugs (HRG Publication #1620) [hide all summaries]
    The single most important risk management strategy the FDA can undertake in the short-term to reduce the publics risk from preventable adverse drug reactions is to go forward as rapidly as possible with regulations that require pharmacists to distribute scientifically accurate, useful written drug information, or Medication Guides, approved by the agency. At the very least, this would provide consumers with a reliable source of information that they can use to protect themselves from preventable injury.

Health Letter Articles

Search results below include Health Letter Articles where your selected drug is a secondary subject of discussion
  • Outrage: New Study: Wait Seven Years to Use New Drugs [hide all summaries]
    (June 2002)
    A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group's drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug's professional product labeling or its outright removal from the market. Three of the authors have close identification with the Health Research Group: its director, Sidney M. Wolfe, and former HRG staffers Drs. Steffi Woolhandler and David Himmelstein. The other co-authors are affiliated with the Harvard Medical School.

SHOW primary search results for itraconazole (ONMEL, SPORANOX, TOLSURA)

Copyright © 2020 Public Citizen's Health Research Group. All rights reserved.